Top 5 Stock Picks of Frank Fu’s CaaS Capital

3. Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

CaaS Capital’s Stake Value: $22,298,000
Percentage of CaaS Capital’s 13F Portfolio: 0.91%
Number of Hedge Fund Holders: 27

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical business that develops drugs to cure diseases that are difficult to treat by silencing the genes that cause them. Among the hedge funds tracked by Insider Monkey, 27 funds reported owning stakes worth $221.66 million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) at the end of Q1 2022, an increase as compared to 26 funds in the previous quarter, holding stakes in the company valued at approximately $186.38 million.

H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and boosted his price objective to $110 from $100 on June 3. According to Trucchio, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) gave helpful information on pulmonary targeted RNA interference therapies candidates for muco-obstructive illnesses, disruptive inflammatory pulmonary diseases, and chronic pulmonary fibrosis.

Marc Schneidman’s Aquilo Capital Management is the biggest shareholder of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), with 1.05 million shares worth $48.17 million. In addition, Frank Fu initiated a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in the first quarter of 2022, buying 484,849 shares of the bio-pharma company, worth $22.30 million.

Here is what Carillon Tower Advisers has to say about Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in its Q3 2021 investor letter:

“Arrowhead Pharmaceuticals develops gene silencing medicines used in the treatment of intractable diseases. Shares of the company’s stock fell after the company announced it was immediately pausing its phase 1/2 clinical study of a drug to be used for the treatment of cystic fibrosis, following a preliminary update that showed signs of local lung inflammation in a chronic toxicology study performed on rats.”